This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medco To Present Results Of National Study On Effect Of Genetic Testing On Patient Medication Adherence At The American College Of Cardiology 61st Annual Scientific Session And Expo

FRANKLIN LAKES, N.J., March 14, 2012 /PRNewswire/ -- The final results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) study will be presented at the American College of Cardiology's 61st Annual Scientific Session & Expo being held March 24-27, 2012, in Chicago, IL. The AKROBATS study is a collaborative effort between the Medco Research Instituteā„¢, a subsidiary of Medco Health Solutions, Inc. (NYSE: MHS) and Quest Diagnostics (NYSE: DGX), the world's leading diagnostic testing company.

(Logo: )

Presentation Details

Session Number: 1258

Session Type: ACC Moderated Poster Contributions

Session Start/End Time: Monday, Mar 26, 2012, 9:30 AM -10:30 AM

Location: McCormick Place South, Hall A

Presentation Number: 1258-376 

Abstract Title: Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. 

Presenter:  Scott L. Charland, Pharm.D., Medco Research Institute


AKROBATS is prospective, nonrandomized intervention trial of the effect of KIF6 testing results reported directly to the patient on statin adherence and persistence over six months.  All eligible intervention and control patients were greater than or equal to 18 years old, new to statin therapy (none 6 months prior), and from the same sponsored plans (which had granted permission for their members to participate in the study). Genetic testing for a common single nucleotide polymorphism (rs20455) resulting in an arginine to tryptophan substitution at position 719 (Trp719Arg) in the kinesin-like protein 6 gene ( KIF6) was conducted and written results returned to the patient within 30 days of initiating statin therapy, and before the first statin prescription refill.  Tested patients were matched to concurrent, non-tested control patients on age, gender, statin prescription distribution channel, and the number of chronic medications at time of statin initiation. The primary endpoint was statin adherence (proportion of days covered; PDC) at six months.  Secondary end points included achievement of adherence (PDC greater than or equal to 0.80) and persistence to statin therapy at six months.  AKROBATS is registered on (NCT01068834).

About Medco Research Institute

Medco Research Institute® is an evidence-based research organization focused solely on novel research, analytics and new discoveries that close the gap between scientific discovery and medical practice for improved patient outcomes and lower overall healthcare costs. More information about the Medco Research Institute's peer-reviewed research can be found at

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs